[CAS NO. 2484919-71-1] RET-IN-19

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2484919-71-1]

Catalog

HY-151377

Brand

MCE

CAS

2484919-71-1

DESCRIPTION [2484919-71-1]

Overview

MDL	-
Molecular Weight	544.62
Molecular Formula	C28H28N6O4S
SMILES	O=C(NC1=NOC(C(C)(C)C)=C1)CC2=CC=C(NC3=C4C(NC(C5=CC=C(S(=O)(C)=O)C=C5)=C4)=NC=N3)C=C2

For research use only. We do not sell to patients.

Summary

RET-IN-19 (compound 59) is a potent RET inhibitor, with IC ₅₀ values of 6.8 and 13.51 nM against RET-wt and RET V804M , respectively. RET-IN-19 shows anticancer activity. RET-IN-19 can be used for non-small cell lung cancer (NSCLC) research ^[1] .

IC50 & Target

EGFR

56.78 ± 4. μM (IC ₅₀ )

Aurora A

0.242 ± 0. μM (IC ₅₀ )

Aurora B

0.536 ± 45 μM (IC ₅₀ )

MAP4K4

3.428 ± 0. μM (IC ₅₀ )

In Vitro

RET-IN-19 (compound 59) shows growth inhibition of LC-2/ad cells which RET-CCDC6 driven, with a GI ₅₀ of 0.1067 ± 0.004 μM ^[1] .
RET-IN-19 (3 μM) shows inhibition of LC-2/ad cells migration ^[1] .
RET-IN-19 inhibits EGFR, Aurora A, Aurora B, Nek2, CSF-1R, MAP4K4, NIK, and RET, with IC ₅₀ values of 56.78 ± 4.94, 0.242 ± 0.036, 0.536 ± 45.12, >200, 1.65 ± 0.235, 3.428 ± 0.150, >10, and 0.0068 ± 0.0003, respectively ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Lakkaniga NR, et al. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. Eur J Med Chem. 2020 Nov 15;206:112691.